SCHEMBL839905

SCHEMBL839905

CSCC[C@H](O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36
RNPEP Q9H4A4 1/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
RECQL P46063 1/20 0.34
SRR Q9GZT4 2/20 0.34
PSAT1 Q9Y617 1/20 0.34
PKM P14618 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839906 1.00 GAA (0.36) GAAKDM4EALOX15RNPEPLMNA
SCHEMBL838502 0.88 RECQL (0.42) GAALMNAMEN1ALDH1A1TSHR
SCHEMBL838503 0.88 RECQL (0.42) GAALMNAMEN1ALDH1A1TSHR
SCHEMBL5970973 0.85 PPARG (0.47) ALDH1A1SRR
SCHEMBL31647804 0.83 FOLH1 (0.39) KDM4EALDH1A1TSHRHSD17B10SRR
SCHEMBL17027649 0.82 PPARG (0.43) KDM4EMEN1ALDH1A1TSHRKMT2A
SCHEMBL1929736 0.81 SMN1; SMN2 (0.42) LMNAALDH1A1HSD17B10NPSR1SRR
SCHEMBL1295811 0.81 SMN1; SMN2 (0.42) LMNAALDH1A1HSD17B10NPSR1SRR
SCHEMBL5970585 0.81 SMN1; SMN2 (0.42) LMNAALDH1A1HSD17B10NPSR1SRR
SCHEMBL5282712 0.80 MAPT (0.39) ALDH1A1SRRPSAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GAA 63/4885KDM4E 3541/4885ALOX15 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.